2023
Impact of frailty on complications and length of stay after minimally invasive adrenalectomy surgery
Ahuja V, Gibson C, Machado N, King J. Impact of frailty on complications and length of stay after minimally invasive adrenalectomy surgery. Surgery 2023, 175: 336-341. PMID: 38049363, DOI: 10.1016/j.surg.2023.10.023.Peer-Reviewed Original ResearchConceptsFrailty indexInvasive adrenalectomySurgical indicationsBenign diseaseMalignant diseaseMost adverse outcomesStay 2 daysImpact of frailtyThirty-day mortalityLength of stayRelationship of ageAdrenalectomy patientsAdrenalectomy proceduresAdrenalectomy surgeryElective adrenalectomyPerioperative outcomesAdrenal surgeryComplication rateOlder patientsAdrenal diseaseMedian lengthSurgical outcomesAdverse outcomesEndocrine disordersEndocrine diseases
2011
Adult glioblastoma multiforme survival in the temozolomide era: A population‐based analysis of Surveillance, Epidemiology, and End Results registries
Darefsky AS, King JT, Dubrow R. Adult glioblastoma multiforme survival in the temozolomide era: A population‐based analysis of Surveillance, Epidemiology, and End Results registries. Cancer 2011, 118: 2163-2172. PMID: 21882183, PMCID: PMC3235223, DOI: 10.1002/cncr.26494.Peer-Reviewed Original ResearchConceptsHazard ratioTemozolomide eraMultivariate-adjusted hazard ratiosEnd Results Program databaseKaplan-Meier methodPopulation-based surveillanceTwo-year survivalAge-stratified analysisConfidence intervalsPopulation-based analysisAge 20 yearsProportional hazards modelProgressive decreaseTemozolomide useOlder patientsSurgical resectionSurvival improvementTreatment advancesProgram databaseGBM patientsHazards modelGBM treatmentAge 20Age groupsGlioblastoma multiforme survival